States gain the option to expand GLP-1 access through Medicaid
A route that did not exist for the lowest-income patients — but optional, so it will be a patchwork.
A route that did not exist for the lowest-income patients — but optional, so it will be a patchwork.
All-in monthly cost at 10 mg
The federal agreement announced alongside the Medicare Bridge gives states the ability to expand access through Medicaid. The operative word is ability.
Access will vary by state, and the states least likely to opt in are frequently those with the highest obesity prevalence.
Compounded preparations are unaffected; no Medicaid programme covers them.
What this changes for what you pay
Most developments in this category move one of three things: the price of the branded product, which programmes are operating, or what may lawfully be compounded. Very few change the prescription requirement, the pharmacy licensing framework or the clinical review behind a prescription.
The cheapest verified compounded route we track currently sits at $215 a month all-in at a 10 mg maintenance dose, about $2,580 for a first year. Where a development moves that figure, our tables move with it on the next build.
How to verify this yourself
Regulatory claims should be checked against the agency rather than against coverage of the agency. FDA publishes warning letters searchable by company name, a shortage database, and its compounding pages. Trial claims should be checked against the registry entry rather than a press release.
Every source behind this item is linked below, and where a story is still moving we say so rather than implying it is settled.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.
Compare every programme on one screen
The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.